Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/355374
Full metadata record
DC FieldValueLanguage
dc.contributor.CRUESPUNIVERSIDADE ESTADUAL DE CAMPINASpt_BR
dc.contributor.authorunicampSantos Neto, Octávio de Oliveira-
dc.typeArtigopt_BR
dc.titleSebaceous hyperplasia: systemic treatment with isotretinoinpt_BR
dc.contributor.authorTagliolatto, Sandra-
dc.contributor.authorde Avelar Alchorne, Mauricio Mota-
dc.contributor.authorSantos Neto, Octavio de Oliveira-
dc.contributor.authorEnokihara, Mauro Yoshiaki-
dc.subjectEnsaio clínicopt_BR
dc.subject.otherlanguageClinical trialpt_BR
dc.description.abstractThe study aimed to verify the therapeutic action of isotretinoin in the treatment of sebaceous hyperplasia. During two months, 20 patients with sebaceous hyperplasia took isotretinoin at a dosage of 1mg/kg per day. Their skin lesions were counted and photographed before and after treatment and re-evaluated two years later. The average number of sebaceous hyperplasia lesions before treatment was 24 per patient. At the end of two months of therapy, the number of lesions decreased to 2 per patient. The statistically analyzed data showed a reduction in the number of lesions following isotretinoin use (p < 0.05). Two years after the end of the treatment, the average number of sebaceous hyperplasia lesions was 4 per patient. There were no severe side effects. Thus, the data analysis suggests that isotretinoin is a safe and effective drug for treating the disease under studypt_BR
dc.relation.ispartofAnais brasileiros de dermatologiapt_BR
dc.relation.ispartofabbreviationAn. brasil. dermatol.pt_BR
dc.publisher.cityRio de Janeiro, RJpt_BR
dc.publisher.countryBrasilpt_BR
dc.publisherSociedade Brasileira de Dermatologiapt_BR
dc.date.issued2015-
dc.date.monthofcirculationMar./Apr.pt_BR
dc.language.isoengpt_BR
dc.description.volume90pt_BR
dc.description.issuenumber2pt_BR
dc.description.firstpage211pt_BR
dc.description.lastpage215pt_BR
dc.rightsAbertopt_BR
dc.sourceWOSpt_BR
dc.identifier.issn0365-0596pt_BR
dc.identifier.eissn1806-4841pt_BR
dc.identifier.doi10.1590/abd1806-4841.20153192pt_BR
dc.identifier.urlhttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962015000200211pt_BR
dc.description.sponsorshipFUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO - FAPESPpt_BR
dc.description.sponsordocumentnumbersem informaçãopt_BR
dc.date.available2021-02-08T19:53:23Z-
dc.date.accessioned2021-02-08T19:53:23Z-
dc.description.provenanceSubmitted by Sanches Olivia (olivias@unicamp.br) on 2021-02-08T19:53:23Z No. of bitstreams: 0. Added 1 bitstream(s) on 2021-05-25T12:09:16Z : No. of bitstreams: 1 000352211800008.pdf: 231749 bytes, checksum: bbba8e0a5cdbd2c5ea9a60eeef7ec16e (MD5)en
dc.description.provenanceMade available in DSpace on 2021-02-08T19:53:23Z (GMT). No. of bitstreams: 0 Previous issue date: 2015en
dc.identifier.urihttp://repositorio.unicamp.br/jspui/handle/REPOSIP/355374-
dc.contributor.departmentsem informaçãopt_BR
dc.contributor.unidadeFaculdade de Ciências Médicaspt_BR
dc.subject.keywordIsotretinoinpt_BR
dc.subject.keywordSebaceous gland diseasespt_BR
dc.subject.keywordTherapies, investigationalpt_BR
dc.identifier.source000352211800008pt_BR
dc.creator.orcid0000-0002-1383-4827pt_BR
dc.type.formArtigopt_BR
Appears in Collections:FCM - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
000352211800008.pdf226.32 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.